FDA Announces Label Change to Nizoral Warning of Risk of Liver and Adrenal Injury

In late July 2013, Americans were notified of a Nizoral label change to warn of liver injury risk. The notification was issued by the FDA due to the drug’s inherent risks.

The drug, which is classified as an anti-fungal and comes in several forms, has been in use for some time now. At this time, the warning was issued solely for the oral version of the drug. However, Nizoral users may want to consider talking to their primary care physicians about the other versions of the drug as well.

We should also mention that the drug is presently marketed under other names both here and abroad. The American version of the drug is often listed as Ketoconazole or Xolegel. In other countries, it is known by at least a half dozen other brand names.

Regardless of the name or form, it has been used to treat a variety of health conditions, including the following:

Lutz-Splendore-Almeida Disease
San Joaquin Valley Fever
Gilchrist’s Disease
Darling’s Disease
Prostate Cancer
Athlete’s Feet
Candidiasis
Ringworm

As we alluded to earlier, the warning was issued because the drug may potentially cause users to develop adrenal insufficiency and hepatotoxicity. However, it can also cause heart problems, depression and a series of other health issues.

If you believe you have been injured by Nizoral, or other products containing ketoconazole, you are welcome to contact The Levensten Law Firm to learn more about your rights. Our lawyers can assist those that may have been impacted by the dangerous drug seek justice against the product’s manufacturer. To schedule an initial consultation with our legal team, call (215) 545-5600.